MCMarta Csanalosi

Marta Csanalosi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Csanalosi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of a personalized mobile application on glucose control in adults with prediabetes and type 2 diabetes: an exploratory pilot randomized controlled trial (Preprint)

    by Elena Lalama, Marta Csanalosi, Stefan Kabisch, Saskia Wilson-Barnes, Lazaros P. Gymnopoulos, Kosmas Dimitropoulos, Konstantinos Rouskas, Argiriou Anagnostis, Ioannis Oikonomidis, Leontios Hadjileontiadis, et al.

    The incidence of type 2 diabetes (T2D) continues to increase, and the lack of individualized therapy strategies hinders patient engagement with and commitment to a healthy lifestyle. The PROTEIN project aimed to facilitate users in choosing healthy living, thereby improving their metabolism and T2D management. This study aims to assess the efficacy of a personalized mobile app to achieve a 5% time in range (TIR) improvement over a 12-week intervention in adults with prediabetes or T2D. We conducted an exploratory pilot randomized controlled trial with 21 individuals with T2D or prediabetes who used a continuous glucose monitoring system and the PROTEIN mobile app for personalized meals and exercise recommendations based on their glucose levels and physical activity. The TIR of the participants increased (P<.05; from 71.8%, SD 27.3% to 76%, SD 28.1%) with individual use of the PROTEIN app but did not achieve a 5% improvement overall; however, given the exploratory design and small sample size, this finding should be interpreted with caution. Glycated hemoglobin, fasting blood glucose, and body weight did not fluctuate throughout the 12-week intervention. The dropout rate was high, and the average duration of use of the PROTEIN app was 42 (range 5-84) days. Our results showed a modest increase in TIR with the use of the PROTEIN app; however, considering the exploratory design and small sample size, this finding should be interpreted as preliminary. Integrating wearables and automated personalization for well-being is an innovative approach that must keep pace with the accelerated development of ever-evolving technologies. The COVID-19 pandemic was a major obstacle to recruitment in our clinical trial. ClinicalTrials.gov NCT05951140; https://clinicaltrials.gov/study/NCT05951140.

  • Open Access

    Assessment of dietary advice delivered by a personalized mobile application to improve glucose control for adults with prediabetes and type 2 diabetes: Randomized Controlled Trial (Preprint)

    by Elena Lalama, Marta Csanalosi, Stefan Kabisch, Saskia Wilson-Barnes, Lazaros P. Gymnopoulos, Kosmas Dimitropoulos, Konstantinos Rouskas, Argiriou Anagnostis, Ioannis Oikonomidis, Leontios Hadjileontiadis, et al.

    BACKGROUND The incidence of type 2 diabetes (T2D) continues to increase, and the lack of individualized therapy strategies hinders patient engagement with and commitment to a healthy lifestyle. The PROTEIN project aimed to facilitate users to choose healthy living, thereby improving their metabolism and T2D management. OBJECTIVE To assess the efficacy of a personalized mobile application to achieve a 5% time in range (TIR) improvement over a 12-week intervention in adults with prediabetes or T2DM. METHODS We conducted a randomized controlled trial (RCT) with 21 individuals with T2D or prediabetes who used a continuous glucose monitoring (CGM) system and the PROTEIN mobile application (PROTEIN app) for personalized meals and exercise recommendations based on their glucose levels and physical activity. RESULTS The TIR of the participants increased (p<0.05; from 71.8% ± 27.3% to 76.0% ± 28.1%) with individual use of the PROTEIN app but did not achieve a 5% improvement overall. Glycated hemoglobin, fasting blood glucose, and body weight did not fluctuate throughout the 12-week intervention. The dropout rate was high and the average duration of use of the PROTEIN app was 42 days (range 5 to 84). CONCLUSIONS Our results showed an improvement in TIR with the use of the PROTEIN-app. Integrating wearables and automated personalization for wellbeing is an innovative approach that must keep pace with the accelerated development of ever-evolving technologies. CLINICALTRIAL ClinicalTrials.gov: registration no. NCT05951140 https://clinicaltrials.gov/study/NCT05951140